Something New for VIVUS Investors to Watch?

After Vivus (Nasdaq: VVUS  ) posted earnings last week, the company's share price took a big hit due to unimpressive sales of obesity drug Qsymia. With competitor Arena Pharmaceuticals (Nasdaq: ARNA  ) and its partner Eisai poised to enter this space with its own drug Belviq in the first quarter of next year, VIVUS might be starting to feel pressure to boost sales.

While investors need to continue watching Qsymia sales quarter to quarter, VIVUS looks determined to expand the possible uses for its flagship drug. In this video, Health Care Analyst Max Macaluso discusses a new clinical study that suggests Qsymia might widen its indication in the future.

The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies are looking to change everything. Newly-approved drugs, including VIVUS' flagship drug, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 14, 2012, at 8:30 AM, PRODOD wrote:

    It is difficult to expand the Rx profile of a drug that is not a 'unique molocule' under any circumstances and, in the case of the so-called 28 week OSA study on Qsymia, it is unclear if Qsymia had any direct effect on OSA or whether the minimal respratory inprovement was the predictable result of the subjects weight loss. In short, the recent "SLEEP" article on Qsymia will not prompt 'off lable' use of Qsymia for OSA.

    Note: No spell check.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2111382, ~/Articles/ArticleHandler.aspx, 10/22/2016 7:45:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 22 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ARNA $1.57 Down -0.02 -1.26%
Arena Pharmaceutic… CAPS Rating: **
VVUS $1.10 Down -0.01 -0.90%
VIVUS CAPS Rating: **